Enveric Biosciences, Inc. (ENVB)
NASDAQ: ENVB · Real-Time Price · USD
0.464
-0.028 (-5.63%)
At close: Nov 4, 2024, 4:00 PM
0.470
+0.006 (1.29%)
After-hours: Nov 4, 2024, 6:51 PM EST

Company Description

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders.

Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health.

The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer.

Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Enveric Biosciences, Inc.
Enveric Biosciences logo
Country United States
Founded 1994
Industry Biotechnology
Sector Healthcare
Employees 7
CEO Joseph Tucker

Contact Details

Address:
4851 Tamiami Trail N, Suite 200
Naples, Florida 34103
United States
Phone 239-302-1707
Website enveric.com

Stock Details

Ticker Symbol ENVB
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000890821
CUSIP Number 29405E208
ISIN Number US29405E2081
Employer ID 95-4484725
SIC Code 2834

Key Executives

Name Position
Dr. Joseph Edward Tucker Ph.D. Chief Executive Officer and Director
Kevin M. Coveney CPA Chief Financial Officer
Dr. Peter J. Facchini Ph.D. Chief Innovation Officer

Latest SEC Filings

Date Type Title
Sep 12, 2024 424B4 Prospectus
Sep 11, 2024 EFFECT Notice of Effectiveness
Sep 9, 2024 UPLOAD Filing
Sep 4, 2024 S-1 General form for registration of securities under the Securities Act of 1933
Aug 22, 2024 8-K Current Report
Aug 12, 2024 10-Q Quarterly Report
Aug 12, 2024 8-K Current Report
Jul 15, 2024 8-K Current Report
Jul 8, 2024 S-3 Registration statement under Securities Act of 1933
May 29, 2024 8-K Current Report